LRRK2 and Parkinson disease: We next set out to perform a first study on patient samples obtained from the LRRK2 cohort consortium (LCC), from all male subjects divided into four groups: idiopathic PD, LRRK2 G2019S carriers manifesting or not manifesting PD as well as healthy controls (Clinical parameters of the subjects are summarized in Table 1).